Study summary · research use only
Superovulation and embryo recovery in goats treated with Ovagen and Folltropin
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this goat study, the authors compared superovulation with Folltropin or Ovagen in goats of feral origin, measuring corpora lutea and embryo numbers and quality. They report mean corpora lutea and embryos of 16.2 +/- 2.1 and 12.6 +/- 1.9 after Ovagen (17 animals) versus 16.3 +/- 1.8 and 10.2 +/- 1.6 after Folltropin (18 animals), with transferable embryos of 11.1 +/- 1.8 and 7.9 +/- 1.4, and note these values did not differ significantly between groups. A significant correlation between corpora lutea and embryo number occurred after Ovagen but not Folltropin, and 22% of Folltropin-treated animals produced abnormal or prematurely regressing corpora lutea, whereas none did after Ovagen.
Abstract
The purpose of the present study was to examine ovulation rates and embryo numbers and quality in goats of feral origin following treatment with either Folltropin (Vetrepharm Inc., Ontario, Canada) or Ovagen (Immuno-Chemical Products Ltd., Auckland). The mean +/- s.e.m. numbers of corpora lutea (CL) and embryos recovered after Ovagen treatment (N = 17 animals) were 16.2 +/- 2.1 and 12.6 +/- 1.9 respectively whereas after Folltropin treatment (N = 18 animals), the respective numbers were 16.3 +/- 1.8 and 10.2 +/- 1.6. The mean +/- s.e.m. numbers of good (i.e. transferable) embryos were 11.1 +/- 1.8 in the Ovagen group and 7.9 +/- 1.4 in the Folltropin group. AII the above values for each of the treatment groups were not significantly different from one another. There was a significant linear relationship between the number of CL and number of embryos (p<0.01; R = 0.925) after Ovagen treatment whereas there was no significant relationship after FolItropin treatment (p>0.05; R = 0.461). The proportions of animals producing more than five recoverable embryos after Ovagen (i.e. 76%) or Folltropin treatment (i.e. 72%) were similar although 22% of the Folltropin treated animals produced abnormal or prematurely regressing CL whereas no such CL were found after Ovagen treatment.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.